Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

NCT04250818 is registered in ClinicalTrials.gov with Texas Tech University Health Sciences Center, El Paso as lead sponsor.

NCT NCT04250818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Phase
Observational
Overall status
Suspended
Start date
July 2, 2019
Completion date
May 31, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic triple-negative breast cancer